Glenmark Pharmaceuticals Ltd said its Swiss arm has entered into an exclusive licensing agreement with Lotus International Pte Ltd for commercialising its innovative nasal spray Ryaltris in Singapore, Hong Kong and Vietnam.

• What is Stock Order : Types, Differences & How Order Works
• India’s Business Activity Hits 3-Month High in Nov Amid Rising Costs
• Trudeau to Cut Sales Tax and Send Checks to Canadians Ahead of Election
• Ashwini Vaishnaw Encourages German Companies to Invest in India
• Flipkart Appoints Dan Bartlett to Board

Under the agreement signed between Glenmark Specialty SA and the wholly-owned subsidiary of Lotus Pharmaceutical Co, Ltd (Lotus), Glenmark will be responsible for the manufacturing and supply of Ryaltris.

On the other hand Lotus will be responsible for its commercialization subject to receipt of regulatory approvals, in these markets, the company said in a statement.